Clinical Trial Update: Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating stereotactic body radiation therapy with aflibercept for uveal melanoma has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Uveal Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2025-09-24